Go Pro
NASDAQ:NTRA

Natera (NTRA) Stock Price, News & Analysis

Natera logo
$326.26 -12.44 (-3.67%)
As of 04:00 PM Eastern

About Natera Stock (NASDAQ:NTRA)

Advanced

Key Stats

Today's Range
$325.66
$339.30
50-Day Range
$228.80
$338.70
52-Week Range
$157.43
$343.18
Volume
832,932 shs
Average Volume
1.36 million shs
Market Capitalization
$47.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$319.38
Consensus Rating
Moderate Buy

Company Overview

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection. The company also provides genetic counseling and supports clinical use through validation studies and peer-reviewed publications.

Natera operates certified clinical laboratories and serves healthcare providers, hospitals, fertility clinics, and biopharmaceutical partners in the United States and in international markets. The company engages in collaborations with clinicians and drug developers to support clinical trials, companion diagnostic development, and translational research. Its offerings are positioned to support both clinical decision-making and research applications across multiple therapeutic areas.

Founded in the mid-2000s and headquartered in the San Francisco Bay Area, Natera is a publicly traded company listed on the Nasdaq. The business emphasizes ongoing research and product development, regulatory compliance, and scientific validation to expand the clinical utility of its genetic testing platforms. Its leadership and scientific teams comprise professionals with experience in genomics, diagnostics, and laboratory medicine.

AI Generated. May Contain Errors.

Natera Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

NTRA MarketRank™: 

Natera scored higher than 54% of companies evaluated by MarketBeat, and ranked 494th out of 920 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Natera has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 15 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Natera is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Natera has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Natera's stock forecast and price target.
  • Earnings Growth

    Earnings for Natera are expected to grow in the coming year, from ($1.02) to $0.01 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Natera is -241.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Natera is -241.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Natera has a P/B Ratio of 26.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Natera's valuation and earnings.
  • Percentage of Shares Shorted

    3.14% of the float of Natera has been sold short.
  • Short Interest Ratio / Days to Cover

    Natera has a short interest ratio ("days to cover") of 2.61, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Natera has recently decreased by 1.60%, indicating that investor sentiment is improving.
  • Dividend Yield

    Natera does not currently pay a dividend.

  • Dividend Growth

    Natera does not have a long track record of dividend growth.

  • News Sentiment

    Natera has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 45 news articles for Natera this week, compared to 11 articles on an average week.
  • Search Interest

    22 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 667% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,704,193.00 in company stock.

  • Percentage Held by Insiders

    5.05% of the stock of Natera is held by insiders.

  • Percentage Held by Institutions

    99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Natera's insider trading history.
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NTRA Stock News Headlines

This coin has everything going for it
Everything is lining up for this coin to surge... The Fed is easing. Liquidity is increasing. Trump's pro-crypto policies are accelerating. The GENIUS Act is reshaping the rules for stablecoins. Institutional barriers are falling. When you get a macro tailwind AND strong fundamentals AND suppressed prices all at once? That's rare. That's the kind of setup I've seen lead to gains of 3,500%... 8,600%... even higher.tc pixel
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts (NTRA)
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.
John Fesko Sells 295 Shares of Natera (NASDAQ:NTRA) Stock
See More Headlines

NTRA Stock Analysis - Frequently Asked Questions

Natera's stock was trading at $229.09 at the start of the year. Since then, NTRA stock has increased by 43.4% and is now trading at $328.59.

Natera, Inc. (NASDAQ:NTRA) released its earnings results on Thursday, August, 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The company's quarterly revenue was up 37.7% on a year-over-year basis.
Read the conference call transcript
.

Natera (NTRA) raised $175 million in an initial public offering on Thursday, July 2nd 2015. The company issued 10,000,000 shares at a price of $17.00-$18.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Top institutional shareholders of Natera include California State Teachers Retirement System (39.08%), BlackRock Inc. (7.62%), Wellington Management Group LLP (2.80%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.58%). Insiders that own company stock include Roelof Botha, Matthew Rabinowitz, Daniel Rabinowitz, John Fesko, Solomon Moshkevich, Steven Leonard Chapman, Jonathan Sheena, Michael Burkes Brophy, James Healy, Roy D Baynes, Gail Boxer Marcus, Herm Rosenman and Rowan E Chapman.
View institutional ownership trends
.

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
8/06/2026
Today
8/28/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NTRA
CIK
1604821
Fax
N/A
Employees
6,140
Year Founded
2004

Price Target and Rating

High Price Target
$375.00
Low Price Target
$172.00
Potential Upside/Downside
-2.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
22 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$208.16 million
Net Margins
-7.11%
Pretax Margin
-9.33%
Return on Equity
-11.38%
Return on Assets
-7.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.00
Quick Ratio
2.85

Sales & Book Value

Annual Sales
$2.71 billion
Price / Sales
17.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.64 per share
Price / Book
25.81

Miscellaneous

Outstanding Shares
144,144,000
Free Float
136,865,000
Market Cap
$47.03 billion
Optionable
Optionable
Beta
1.51

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:NTRA) was last updated on 8/28/2026 by MarketBeat.com Staff.
From Our Partners